Singapore: Pathwork Diagnostics, the innovator of Pathwork Tissue of Origin Test and a pioneer in creating genomics-based diagnostics in oncology, has entered into an agreement with Kindstar Global to provide them with the FDA-cleared in vitro diagnostic (IVD) kit version of the Pathwork Tissue of Origin Test. The collaboration will allow Kindstar to offer an important new test for cancer diagnosis in China.

"The Pathwork Tissue of Origin test is a valuable complement to immunohistochemistry in determining site of origin for lesions that are poorly differentiated or show staining and morphology patterns that are inconsistent with clinical expectations," said Mr Lee McCracken, president and CEO of Pathwork Diagnostics. "We are pleased to partner with Kindstar and provide the rapidly expanding Chinese market with access to our innovative test."

"We are excited about offering the Tissue of Origin test," says Mr Shiang Huang, founder and CEO of Kindstar. "Having access to this test will allow us to expand the current testing services we offer Chinese physicians and position our business as the leading diagnostic company in the fastest growing market in the world."

The agreement supports Pathwork's efforts to improve cancer care worldwide, expands Pathwork's international network of test and service providers, and is the first IVD kit agreement for Pathwork.